RHYTHM PHARMACEUTICALS, INC. (RYTM) FY2026 YTD Q2 P&L / Income Statement

RHYTHM PHARMACEUTICALS, INC. (RYTM) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

131,367,000 US dollars

Cost of sales

16,088,000 US dollars

Gross profit (calculated)

115,279,000 US dollars

Operating expenses (calculated)

216,192,000 US dollars

Loss from operations

negative 100,913,000 US dollars

Total other expense, net

negative 3,035,000 US dollars

Loss before income taxes

negative 103,948,000 US dollars

Provision for income taxes

989,000 US dollars

Net loss

negative 104,937,000 US dollars

Product revenue, net

131,367,000 US dollars

License revenue

0 US dollars

Research and development

85,153,000 US dollars

Selling, general, and administrative

131,039,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.